Home › Research › Drug development
Metformin mitigates dementia risk among individuals with type 2 diabetes
Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Praise Fawehinmi, Abdulrahmon Moradeyo, Stephen Igwe, Rebecca Ojabo, Badrudeen Olalekan Alabi et al.. Clinical diabetes and endocrinology, 2024-05-10
Topic: Drug trials: efficacy and safety
This mini-narrative review explores the relationship between diabetes and dementia, focusing on the potential mitigating role of metformin in reducing cognitive decline among individuals with type 2 diabetes. The interplay of factors such as glycemic control, diabetic complications, and lifestyle influences characterises diabetes-related dementia. This review emphasises the significance of comprehensive diabetes management in addressing the heightened risk of dementia in this population. Methodologically, the review synthesises evidence from 23 studies retrieved through searches on PubMed, Embase, Google Scholar, and Scopus. Current evidence suggests a predominantly positive association between metformin use and a reduced risk of dementia in individuals with diabetes. However, the review shows the complex nature of these outcomes, revealing variations in results in some studies. These discrepancies show the importance of exploring dose-response relationships, long-term effects, and demographic diversity to unravel the complexities of metformin's impact on cognitive health. Limitations in the existing body of research, including methodological disparities and confounding variables, necessitate refined approaches in future studies. Large-scale prospective longitudinal studies and randomised controlled trials focusing specifically on cognitive effects are recommended. Propensity score matching and exploration of molecular mechanisms can enhance the validity of findings in clinical practice. From a clinical perspective, metformin can serve as a potential adjunctive therapy for individuals with diabetes at risk of cognitive decline.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Aderinto, N., Olatunji, G., Kokori, E., Fawehinmi, P., Moradeyo, A., Igwe, S., et al. (2024). Metformin mitigates dementia risk among individuals with type 2 diabetes. Clinical diabetes and endocrinology. https://doi.org/10.1186/s40842-024-00168-7
Vancouver
Aderinto N, Olatunji G, Kokori E, Fawehinmi P, Moradeyo A, Igwe S, et al. Metformin mitigates dementia risk among individuals with type 2 diabetes. Clinical diabetes and endocrinology. 2024. doi:10.1186/s40842-024-00168-7. PMID: 38725077.
BibTeX
@article{aderinto2024-38725077,
author = {Aderinto, Nicholas and Olatunji, Gbolahan and Kokori, Emmanuel and Fawehinmi, Praise and Moradeyo, Abdulrahmon and Igwe, Stephen and Ojabo, Rebecca and Alabi, Badrudeen Olalekan and others},
title = {{Metformin mitigates dementia risk among individuals with type 2 diabetes}},
journal = {Clinical diabetes and endocrinology},
year = {2024},
doi = {10.1186/s40842-024-00168-7},
pmid = {38725077},
url = {https://doi.org/10.1186/s40842-024-00168-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, the review shows the complex nature of these outcomes, revealing variations in results in some studies.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designlongitudinal study
- Evidence strengthHigh
How this study scored 63/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 35 of the 56 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical diabetes and endocrinology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38725077) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 35 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 35 of the 56 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Drug development
Also tagged “metabolic-syndrome”
304 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 304 tagged studies.